Document is current
Any future updates will be listed below
-
Authors
Bian, Xiaohui
Conley, Sabena M.
Eirin, Alfonso
Zimmerman Zuckerman, Eric A.
Smith, Anastasia L.
Gowan, Cody C.
Snow, Zachary K.
Jarmi, Tambi
Farres, Houssam
Erben, Young M.
Hakaim, Albert G.
Dietz, Matthew A.
Zubair, Abba C.
Wyles, Saranya P.
Wolfram, Joy V.
Lerman, Lilach O.
Hickson, LaTonya J. https://orcid.org/0000-0002-7485-336X
-
Funding
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (DK109134, DK123492)
- License Information
-
More Information
Article History
Received: 1 January 2022
Accepted: 8 March 2023
First Online: 22 March 2023
Declarations
:
: The studies involving human participants were reviewed and approved by Mayo Clinic Institutional Review Board (IRB: 15-000933; “Stem Cells in Chronic Kidney Disease”) in May 2015. This study adheres to the Declaration of Helsinki. Study participants provided their written informed consent to participate in this study.
: Not applicable.
: Lilach Lerman, MD, PhD, received grant funding from Novo Nordisk and is an advisor to Weijian Technologies and AstraZeneca. The remaining authors declare that they have no competing interests.
